Table 1 Characteristics of the validation study population (n = 129)
Characteristic | n (%) |
|---|---|
Age in years | 59 ± 13* |
Female gender | 108 (83.7%) |
Education level | |
Illiterate | 1 (0.8%) |
Up to 1st grade | 82 (64.6%) |
Up to 2nd grade | 36 (28.3%) |
Superior | 8 (6.3%) |
BMI | 26 ± 4* |
Disease duration (years) | 13 (7–23)** |
RF or anti-CCP positive | 111 (86.7%) |
Using corticoid | 44 (34.1%) |
Using conventional synthetic DMARD | 105 (81.4%) |
Using biologic agents | 40 (31.0%) |
Rheumatoid arthritis core data set measures | |
Patient measures | |
MDHAQ (0–3) | 1.0 (0.4–1.5)** |
HAQ (0–3) | 1.1 (0.6–1.7)** |
Pain VAS (0–10) | 6.0 (3.5–8.0)** |
Global Assessment (0–10) | 5.0 (2.0–7.5)** |
Physician measures | |
Tender 28-joint count | 2.0 (0.0–4.5)** |
Swollen 28-joint count | 1.0 (0.0–4.0)** |
Evaluator global assessment of disease activity (0–10) | 3.0 (0.0–5.0)** |
Laboratory measures | |
Erythrocyte sedimention rate (mm/h) [n = 128] | 26.5 (15.0—44.0)** |
C-reactive protein (mg/dl) [n = 127] | 5.4 (2.2—13.0)** |
Composite disease activity index | |
RAPID3 | 15.0 (8.8–19.6)** |
CDAI | 11.3 (4.0–20.0)** |
SDAI [n = 127] | 12.1 (4.7–21.8)** |
DAS28 (ESR) | 3.8 ± 1.6* |